Related Experiment Video

Updated: Sep 6, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K

Cardiovascular Implications of microRNAs in Coronavirus Disease 2019

Carmine Izzo1, Valeria Visco1, Jessica Gambardella1

  • 1Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy (C.I., V.V., G.J.F., A.R., M.R.R., A.L.T., A.C., P.D.P., C.V., M.C.); Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy (J.G., G.I.); Department of Medicine, Einstein-Sinai Diabetes Research Center, The Fleischer Institute for Diabetes and Metabolism, Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York, New York (J.G.); Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona," Salerno, Italy (N.V.); and Vascular Physiopathology Unit, IRCCS Neuromed, Pozzilli, Italy (A.C., C.V.).

The Journal of Pharmacology and Experimental Therapeutics
|July 2, 2022
PubMed

Insights

MicroRNAs (miRNAs) are key to understanding cardiovascular complications in COVID-19. These molecules show promise as biomarkers and therapeutic targets for managing heart and blood vessel damage during SARS-CoV-2 infection.

Area of Science:

  • Biomedical Research
  • Molecular Biology
  • Cardiology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, presents significant global health challenges.
  • Cardiovascular complications are a major concern in COVID-19 patients, with limited strategies for prevention or treatment.
  • Identifying molecular contributors to these cardiovascular issues is vital for developing diagnostics and therapeutics.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) in the cardiovascular complications associated with COVID-19.
  • To explore the potential of miRNAs as biomarkers for cardiac and vascular damage in SARS-CoV-2 infection.
  • To discuss miRNAs as prognostic predictors and potential therapeutic targets for COVID-19-related cardiovascular events.

Main Methods:

  • Literature review and analysis of existing research on miRNAs and COVID-19.
  • Focus on studies investigating molecular mechanisms linking SARS-CoV-2 infection to cardiovascular manifestations.
  • Synthesis of evidence regarding the diagnostic and prognostic value of miRNAs in this context.

Main Results:

  • MicroRNAs play a significant role in the pathogenesis of cardiovascular complications in COVID-19.
  • Specific miRNAs are implicated in both cardiac and vascular damage resulting from SARS-CoV-2 infection.
  • Evidence suggests miRNAs can serve as reliable biomarkers and predictors of cardiovascular outcomes.

Conclusions:

  • MicroRNAs are crucial molecular mediators of cardiovascular complications in COVID-19.
  • miRNAs hold significant potential as early biomarkers and prognostic indicators for cardiovascular events in COVID-19 patients.
  • Targeting miRNAs may offer novel therapeutic strategies for managing cardiovascular sequelae of SARS-CoV-2 infection.

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.2K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.6K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
32
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
23
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
20
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
28